Skip to main content
Keeping you afloat amidst the rising sea of regulations

Late Night Budget Bill Contains Provisions of Interest to Big Pharma

The Bipartisan Budget Act of 2018 was signed into law on February 9, 2018 in order to avert another shut-down of the federal government. Although the Act contains appropriations and budgetary provisions typical of such a bill, it also includes several provisions that are attracting the attention of pharmaceutical manufacturers, pharmacies, Medicare Part D Plans, and others in the industry.   

Washington’s Best Kept Secret Revealed: What’s in the Senate Health Care Bill

After weeks of closed-door meetings about the content of the Senate’s health care bill, Senate Republicans released a “discussion draft” of their legislation on Thursday. The bill, titled the “Better Care Reconciliation Act of 2017” or BCRA, is the Senate’s response to the bill passed by the House of Representatives in May.

Sonja Nesbit Published in AHLA Weekly

Arent Fox’s Senior Government Relations Director Sonja Nesbit was recently published in American Health Lawyers Association (AHLA) Weekly in an article titled “The Outlook on Repealing and Replacing the ACA.” In the article, Sonja addresses the recent presidential election and the future of the Affordable Care Act (ACA).To read the AHLA article, click here. 

AHA and FAH Send Joint Letter to Congressional Leaders on ACA Reform

On December 6, 2016, the American Hospital Association (AHA) and the Federation of American Hospitals (FAH), the two leading national hospital associations, sent a joint letter to Speaker of the House Paul Ryan and Senate Majority Leader Mitch McConnell about Congress’s approach to the ACA after President-elect Trump takes office. Both groups are essentially asking for protection from cuts in reimbursement that might take place in the process of repealing, replacing, or reforming the law.

Podcast: What's Next For Obamacare (Part 2)

  With President-elect Donald Trump and a new Congress ready to take office in January, the US health care system has reached a pivotal moment. In particular, the overarching question facing the industry and employers across the country is what will become of President Barack Obama's signature legislation, the Affordable Care Act?

Podcast: What's Next For Obamacare (Part 1)

With President-Elect Donald Trump and a new Congress ready to take office in January, the US health care system has reached a pivotal moment. In particular, the overarching question facing the industry and employers across the country is what will become of President Barack Obama's signature legislation, the Affordable Care Act?

What the 2016 Election Means for Health Care

We expect substantial activity on issues related to health care, both in terms of individual medical insurance, entitlement programs such as Medicaid, drug pricing, stimulation of medical innovation, and possibly marijuana reforms.  It is not easy to predict with much certainty what Donald Trump's health care policy would look like now that he has been elected, but his statements and issue papers released by his campaign offer some insight as to his main priorities.   Read the full analysis

Drug Manufacturers Participating in 340B Program Must Execute New Pricing Agreement Addendum

Recently, the Health Resources and Services Administration (HRSA) released a new addendum to amend the existing Pharmaceutical Pricing Agreements (PPA) that drug manufacturers participating in the 340B Drug Pricing Program (340B Program) must have in place with the Secretary of Health and Human Services (HHS).

What the Election Means for Affordable Care Act

What Happened? On September 16, Arent Fox LLP hosted an interactive discussion featuring two of our health policy authorities on what the health care community can expect for the Affordable Care Act following November’s election. What You Should Know The hour-long conversation touched on a number of important topics. The key takeaways included:

New Dispute Resolution Process Finally Proposed for 340B Program: Abundant Opportunity for Comment by Stakeholders

On August 12, 2016, the Health Resources and Services Administration published a proposed rule setting forth the requirements and procedures of the administrative dispute resolution process applicable to all covered entities and drug manufacturers participating in the 340B Drug Pricing Program. Comments on the Proposed Rule are due on or before October 11, 2016.